Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Claudin 18.2 Targeted Therapy Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The claudin 18.2 targeted therapy market has experienced rapid expansion over the past few years. Forecasts indicate a rise from $1.6 billion in 2025 to $1.98 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 23.7%. Historically, this market’s expansion has been driven by factors such as the increasing incidence of gastric and gastrointestinal cancers, progress in antibody engineering technologies, an increase in oncology-focused clinical trials, greater investments in targeted cancer treatments, and enhanced comprehension of claudin protein biology.
The claudin 18.2 targeted therapy market is anticipated to experience substantial expansion in the coming years. It is projected to reach $4.61 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 23.5%. This growth during the forecast period is propelled by factors such as increasing regulatory approvals for targeted oncology drugs, a rising demand for personalized cancer treatment, the broadening of combination therapy approaches, growing investments in the oncology pipeline, and the increased adoption of precision diagnostics. Prominent trends expected over the forecast period include a heightened focus on biomarker-driven oncology therapies, the rising development of claudin 18.2 monoclonal antibodies, an expanding range of indication-specific targeted treatments, enhanced integration of companion diagnostics, and an increase in strategic collaborations within precision oncology.
Get A Free Sample Report With In-Depth Market Insights:
Claudin 18.2 Targeted Therapy Market Growth Drivers: What’s Behind The Acceleration?
The escalating occurrence of gastrointestinal cancers is anticipated to boost the claudin 18.2 targeted therapy market’s growth. Gastrointestinal (GI) cancers are defined as malignant tumors forming in any part of the digestive tract, from the esophagus to the rectum. This increase in GI cancers is largely attributed to unhealthy diets, particularly those high in processed foods and low in fiber, which promote gut inflammation and raise cancer risk. Claudin 18.2 targeted therapy addresses gastrointestinal cancers by specifically targeting the Claudin 18.2 protein, which is overexpressed on cancer cells. This allows therapeutic agents like drugs or antibodies to destroy cancer cells while leaving healthy tissue intact, thereby improving treatment outcomes. For instance, data from the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicated that 147,931 new colorectal cancer cases were reported in 2022, and 53,779 deaths from colorectal cancer were recorded in 2023. Thus, the growing incidence of gastrointestinal cancers is a primary driver for the expansion of the Claudin 18.2 targeted therapy market.
Claudin 18.2 Targeted Therapy Market Segmentation And Category Overview
The claudin 18.2 targeted therapy market covered in this report is segmented –
1) By Therapy Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types
2) By Indication: Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications
3) By Route Of Administration: Intravenous, Oral, Other Route Of Administrations
4) By End-User: Hospitals, Oncology Centers, Research Institutes, Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies
3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
4) By Other Therapy Types: Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors
Claudin 18.2 Targeted Therapy Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies operating within the claudin 18.2 targeted therapy market are concentrating on developing innovative solutions, such as monoclonal antibodies, with the aim of specifically targeting claudin 18.2-expressing cancer cells and enhancing treatment results. A monoclonal antibody is a protein engineered in a laboratory to bind precisely to a single target, such as a protein on the surface of cancer cells, thereby assisting the immune system in recognizing and attacking these cells. For instance, in March 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, received approval from Japan’s Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab) for the treatment of patients with CLDN18.2-positive cancer. This targeted therapy for advanced gastric and gastroesophageal junction cancer selectively attaches to the CLDN18.2 protein on tumor cells, activating the immune system to destroy them. Clinical trials indicated that it significantly improves progression-free and overall survival when administered with chemotherapy compared to chemotherapy alone. This innovative therapy thus provides a new, effective option for patients with HER2-negative, CLDN18.2-positive tumors, addressing an unmet need in aggressive gastric cancer.
Claudin 18.2 Targeted Therapy Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.
View The Full Claudin 18.2 Targeted Therapy Market Report:
Claudin 18.2 Targeted Therapy Market Regional Analysis And Leading Geography
Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2025. The regions covered in the claudin 18.2 targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
